NDA 201277 · Bayer Hlthcare
Gadavist
Gadobutrol · Intravenous · Gadolinium-based Contrast Agent
NovelLast checked: Nov 19, 2026Latest source record: Jul 28, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2011
Mar 14, 2011
Approved uses
5
Original approval plus efficacy supplements
Registered trials
63
22 Phase 3, 10 recruiting
FAERS reports
4,907
2,187 serious, 189 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS Risk Associated with Intrathecal Use Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. GADAVIST is not approved for intrathecal use [see Warnings and Precautions (5.1) ]. Nephrogenic Systemic Fibrosis GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of GADAVIST in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs. The risk for NSF appears highest among patients with: Chronic, severe kidney disease (GFR < 30 mL/min/1.73m 2 ), or Acute kidney injury....
What it is approved for
From the label in effect Sep 11, 2026.
GADAVIST is indicated for: Magnetic resonance imaging (MRI) of the central nervous system (CNS) to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity in adult and pediatric patients including term neonates MRI of the breast to assess the presence and extent of malignant breast disease in adult patients Magnetic resonance angiography (MRA) to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients including term neonates Cardiac MRI (CMRI) to assess myocardial perfusion (stress, rest) and late gadolinium enhancement in adult patients with known or suspected coronary artery disease (CAD) GADAVIST is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging (MRI): To detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients including term neonates To assess the presence and extent of malignant breast disease in adult patients To evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients including term neonates To assess myocardial perfusion (stress, rest) and late gadolinium enhancement in adult patients with known or suspected coronary artery disease (CAD) ( 1 )
Mechanism: Gadobutrol is a paramagnetic molecule (macrocyclic non-ionic complex of gadolinium) that develops a magnetic moment when placed in a magnetic field. The magnetic moment alters the relaxation rates of water protons in its vicinity in the body, leading to an increase in signal intensity (brightness) of tissues.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 12, 2019 Supplement 17 · Efficacy LabelLetter
- Apr 27, 2016 Supplement 11 · Efficacy LetterLabel
- Dec 29, 2014 Supplement 8 · Efficacy · priority review LabelPediatric Medical ReviewPediatric Clinical Pharmacology Review
- Jun 11, 2014 Supplement 7 · Efficacy Letter
- Mar 14, 2011 Original approval · Type 1 - New Molecular Entity NovelLabelSummary ReviewPediatric Medical Review
6 products under this application
- GADAVIST · GADOBUTROL 18.1416GM/30ML (604.72MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
- GADAVIST · GADOBUTROL 6.0472GM/10ML (604.72MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
- GADAVIST · GADOBUTROL 39.3068GM/65ML (604.72MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
- GADAVIST · GADOBUTROL 9.0708GM/15ML (604.72MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
- GADAVIST · GADOBUTROL 4.5354GM/7.5ML (604.72MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
- GADAVIST · GADOBUTROL 1.20944GM/2ML (604.72MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Gadobutrol" as an intervention, any sponsor and status, largest first.
GuerbetIndustry
NCT04373564 · 2,076 participants (planned) · Start Mar 24, 2021 · Primary completion Dec 31, 2028
Drug: Gadoxetate disodium; Gadobenate dimeglumine and 4 more · For: Motor Function; Cognitive Function; Contrast Media
Sites: Scottsdale, Arizona; New Haven, Connecticut; Chicago, Illinois · 51 sites in all
- Investigational MRI Clinical Software and HardwareActive, not recruiting
Northwestern UniversityAcademic, hospital or other
NCT05215132 · 2,000 participants (planned) · Start Dec 19, 2019 · Primary completion Jan 31, 2028
Drug: Gadavist 2Ml Solution for Injection · For: Image, Body
Sites: Chicago, Illinois
- The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States StudyPivotal-lookingRecruiting
Brigham and Women's HospitalAcademic, hospital or other
NCT06854458 · 1,000 participants (planned) · Start Jun 27, 2025 · Primary completion Jan 2029
Drug: Gadavist; Vasodilator · For: Ischemic Heart Disease (IHD); Cardiac Magnetic Resonance Imaging; Myocardial Blood Flow
Sites: San Francisco, California; Louisville, Kentucky; Boston, Massachusetts · 13 sites in all
BayerBayer (BAYRY)
NCT00828737 · 927 participants · Start Dec 2008 · Primary completion Jan 2015
Drug: Gadobutrol (Gadovist, BAY86-4875) · For: Fibrosis; Renal Impairment
Sites: Adelaide, Australia; Clayton, Australia; Geelong, Australia · 70 sites in all
- A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult PatientsPivotal-lookingRecruiting
GE HealthcareIndustry
NCT07472491 · 640 participants (planned) · Start Apr 1, 2026 · Primary completion Nov 30, 2027
Drug: Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL; Gadobutrol · For: Known or Highly Suspected Central Nervous System (CNS) Lesion; Known or Highly Suspected Body (Excluding CNS) Lesion
Sites: Rochester, Minnesota; The Woodlands, Texas; Tbilisi, Georgia · 7 sites in all
- Gadobutrol Enhanced MRA of the Supra-aortic VesselsPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT01344447 · 479 participants · Start May 12, 2011 · Primary completion May 28, 2014
Drug: Gadobutrol (Gadovist, BAY86-4875) · For: Carotid Stenosis
Sites: Tucson, Arizona; Jacksonville, Florida; Savannah, Georgia · 56 sites in all
- Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)Pivotal-lookingCompleted
BayerBayer (BAYRY)
NCT01890434 · 478 participants · Start Aug 26, 2013 · Primary completion Aug 6, 2016
Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875) · For: Coronary Artery Disease
Sites: Tucson, Arizona; Los Angeles, California; Atlanta, Georgia · 24 sites in all
- Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)Pivotal-lookingCompleted
BayerBayer (BAYRY)
NCT01104584 · 460 participants · Start May 2010 · Primary completion Sep 2011
Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875) · For: Breast Cancer
Sites: Tucson, Arizona; Oakland, California; Englewood, Colorado · 48 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- urticaria1,188
- nausea890
- vomiting742
- pruritus730
- dyspnoea455
- erythema375
- dizziness244
- rash244
- cough231
- headache222
- throat irritation184
- contrast media reaction168
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 1 |
| 2011 | 103 |
| 2012 | 442 |
| 2013 | 327 |
| 2014 | 364 |
| 2015 | 317 |
| 2016 | 373 |
| 2017 | 414 |
| 2018 | 310 |
| 2019 | 266 |
| 2020 | 177 |
| 2021 | 325 |
| 2022 | 307 |
| 2023 | 330 |
| 2024 | 353 |
| 2025 | 301 |
| 2026 | 197 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Gadavist* (Gadobutrol*) · HCPCS A9585
2024 spending
$6.7M
Beneficiaries
224,477
263,032 claims
Per beneficiary
$30
2024 ASP limit $0.32 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $6,005,367 |
| 2021 | $6,792,125 |
| 2022 | $6,535,733 |
| 2023 | $6,720,565 |
| 2024 | $6,698,098 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.
Woolen SA, Shankar PR, Gagnier JJ, et al. · JAMA Intern Med 2020 · Meta-Analysis, Systematic Review
- Efficacy and Safety of Gadopiclenol for Contrast-Enhanced MRI of the Central Nervous System: The PICTURE Randomized Clinical Trial.
Loevner LA, Kolumban B, Hutóczki G, et al. · Invest Radiol 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Stress Perfusion Cardiac Magnetic Resonance vs SPECT Imaging for Detection of Coronary Artery Disease.
Arai AE, Schulz-Menger J, Shah DJ, et al. · J Am Coll Cardiol 2023 · Clinical Trial, Phase III, Multicenter Study
- Gadobutrol-Enhanced Cardiac Magnetic Resonance Imaging for Detection of Coronary Artery Disease.
Arai AE, Schulz-Menger J, Berman D, et al. · J Am Coll Cardiol 2020 · Clinical Trial, Phase III, Research Support, N.I.H., Intramural
- Relative Conspicuity of Gadolinium-Based Contrast Agents in Interventional Pain Procedures.
Maus TP, Schueler BA, Magnuson DJ, et al. · Pain Med 2017 · Controlled Clinical Trial
- Intracranial vessel wall imaging at 7.0-T MRI.
van der Kolk AG, Zwanenburg JJ, Brundel M, et al. · Stroke 2011 · Clinical Trial, Research Support, Non-U.S. Gov't
Sponsor: Bayer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.